Cargando…

Subcellular Performance of Nanoparticles in Cancer Therapy

With the advent of nanotechnology, various modes of traditional treatment strategies have been transformed extensively owing to the advantageous morphological, physiochemical, and functional attributes of nano-sized materials, which are of particular interest in diverse biomedical applications, such...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chen-Guang, Han, Ya-Hui, Kankala, Ranjith Kumar, Wang, Shi-Bin, Chen, Ai-Zheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008395/
https://www.ncbi.nlm.nih.gov/pubmed/32103936
http://dx.doi.org/10.2147/IJN.S226186
_version_ 1783495464792883200
author Liu, Chen-Guang
Han, Ya-Hui
Kankala, Ranjith Kumar
Wang, Shi-Bin
Chen, Ai-Zheng
author_facet Liu, Chen-Guang
Han, Ya-Hui
Kankala, Ranjith Kumar
Wang, Shi-Bin
Chen, Ai-Zheng
author_sort Liu, Chen-Guang
collection PubMed
description With the advent of nanotechnology, various modes of traditional treatment strategies have been transformed extensively owing to the advantageous morphological, physiochemical, and functional attributes of nano-sized materials, which are of particular interest in diverse biomedical applications, such as diagnostics, sensing, imaging, and drug delivery. Despite their success in delivering therapeutic agents, several traditional nanocarriers often end up with deprived selectivity and undesired therapeutic outcome, which significantly limit their clinical applicability. Further advancements in terms of improved selectivity to exhibit desired therapeutic outcome toward ablating cancer cells have been predominantly made focusing on the precise entry of nanoparticles into tumor cells via targeting ligands, and subsequent delivery of therapeutic cargo in response to specific biological or external stimuli. However, there is enough room intracellularly, where diverse small-sized nanomaterials can accumulate and significantly exert potentially specific mechanisms of antitumor effects toward activation of precise cancer cell death pathways that can be explored. In this review, we aim to summarize the intracellular pathways of nanoparticles, highlighting the principles and state of their destructive effects in the subcellular structures as well as the current limitations of conventional therapeutic approaches. Next, we give an overview of subcellular performances and the fate of internalized nanoparticles under various organelle circumstances, particularly endosome or lysosome, mitochondria, nucleus, endoplasmic reticulum, and Golgi apparatus, by comprehensively emphasizing the unique mechanisms with a series of interesting reports. Moreover, intracellular transformation of the internalized nanoparticles, prominent outcome and potential affluence of these interdependent subcellular components in cancer therapy are emphasized. Finally, we conclude with perspectives with a focus on the contemporary challenges in their clinical applicability.
format Online
Article
Text
id pubmed-7008395
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-70083952020-02-26 Subcellular Performance of Nanoparticles in Cancer Therapy Liu, Chen-Guang Han, Ya-Hui Kankala, Ranjith Kumar Wang, Shi-Bin Chen, Ai-Zheng Int J Nanomedicine Review With the advent of nanotechnology, various modes of traditional treatment strategies have been transformed extensively owing to the advantageous morphological, physiochemical, and functional attributes of nano-sized materials, which are of particular interest in diverse biomedical applications, such as diagnostics, sensing, imaging, and drug delivery. Despite their success in delivering therapeutic agents, several traditional nanocarriers often end up with deprived selectivity and undesired therapeutic outcome, which significantly limit their clinical applicability. Further advancements in terms of improved selectivity to exhibit desired therapeutic outcome toward ablating cancer cells have been predominantly made focusing on the precise entry of nanoparticles into tumor cells via targeting ligands, and subsequent delivery of therapeutic cargo in response to specific biological or external stimuli. However, there is enough room intracellularly, where diverse small-sized nanomaterials can accumulate and significantly exert potentially specific mechanisms of antitumor effects toward activation of precise cancer cell death pathways that can be explored. In this review, we aim to summarize the intracellular pathways of nanoparticles, highlighting the principles and state of their destructive effects in the subcellular structures as well as the current limitations of conventional therapeutic approaches. Next, we give an overview of subcellular performances and the fate of internalized nanoparticles under various organelle circumstances, particularly endosome or lysosome, mitochondria, nucleus, endoplasmic reticulum, and Golgi apparatus, by comprehensively emphasizing the unique mechanisms with a series of interesting reports. Moreover, intracellular transformation of the internalized nanoparticles, prominent outcome and potential affluence of these interdependent subcellular components in cancer therapy are emphasized. Finally, we conclude with perspectives with a focus on the contemporary challenges in their clinical applicability. Dove 2020-02-05 /pmc/articles/PMC7008395/ /pubmed/32103936 http://dx.doi.org/10.2147/IJN.S226186 Text en © 2020 Liu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Liu, Chen-Guang
Han, Ya-Hui
Kankala, Ranjith Kumar
Wang, Shi-Bin
Chen, Ai-Zheng
Subcellular Performance of Nanoparticles in Cancer Therapy
title Subcellular Performance of Nanoparticles in Cancer Therapy
title_full Subcellular Performance of Nanoparticles in Cancer Therapy
title_fullStr Subcellular Performance of Nanoparticles in Cancer Therapy
title_full_unstemmed Subcellular Performance of Nanoparticles in Cancer Therapy
title_short Subcellular Performance of Nanoparticles in Cancer Therapy
title_sort subcellular performance of nanoparticles in cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008395/
https://www.ncbi.nlm.nih.gov/pubmed/32103936
http://dx.doi.org/10.2147/IJN.S226186
work_keys_str_mv AT liuchenguang subcellularperformanceofnanoparticlesincancertherapy
AT hanyahui subcellularperformanceofnanoparticlesincancertherapy
AT kankalaranjithkumar subcellularperformanceofnanoparticlesincancertherapy
AT wangshibin subcellularperformanceofnanoparticlesincancertherapy
AT chenaizheng subcellularperformanceofnanoparticlesincancertherapy